US EditionJ INTS BIO to Present Global Clinical Results from JIN-A02, a Fourth-Generation EGFR-TKI, at ASCO 2025
- On June 1, 2025, in Seoul, Korea, J INTS BIO revealed preliminary findings from their worldwide Phase 1/2 clinical study of JIN-A02, a fourth-generation EGFR-TKI, with a presentation scheduled at ASCO 2025 in Chicago.
- The trial addresses resistance mutations like C797S, which emerge after failure of third-generation EGFR-TKIs, the current first-line treatment for EGFR-mutant NSCLC.
- Key findings showed confirmed partial responses across 50mg, 100mg, and 300mg doses, with a 77.3% tumor reduction at 50mg sustained over six cycles and notable brain metastases reduction at higher doses.
- JIN-A02 exhibited no dose-limiting toxicities up to 300mg, with mostly mild adverse events common to EGFR inhibitors, supporting an excellent safety profile and prolonged patient treatment durations.
- J INTS BIO earned selection for the government’s '2025 Baby Unicorn Fostering Project', securing dual funding to accelerate Phase 2 trials and global expansion over two years alongside private investment.
Insights by Ground AI
Does this summary seem wrong?
74 Articles
74 Articles
Coverage Details
Total News Sources74
Leaning Left4Leaning Right10Center23Last UpdatedBias Distribution62% Center
Bias Distribution
- 62% of the sources are Center
62% Center
11%
C 62%
R 27%
Factuality
To view factuality data please Upgrade to Premium
